Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 2/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.36 |
| ▸ | TUBB | P07437 | 1/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.36 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.36 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.36 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.36 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.36 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.36 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.36 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | PRKACG | P22612 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7939010 | 0.89 | PPARG (0.39) | PPARGLCKRXRATUBB4ATUBB | |
| SCHEMBL8681338 | 0.87 | PPARG (0.38) | PPARGRXRATUBB4ATUBBTUBA3C | |
| SCHEMBL7632790 | 0.86 | LRRK2 (0.38) | PPARGRXRAMAPT | |
| SCHEMBL5712317 | 0.86 | PPARG (0.48) | PPARGRXRAMAPTMEN1KMT2A | |
| SCHEMBL5712320 | 0.86 | PPARG (0.48) | PPARGRXRAMAPTMEN1KMT2A | |
| SCHEMBL7937486 | 0.85 | MEN1 (0.33) | PPARGRXRAMAPTMEN1KMT2A | |
| SCHEMBL9710902 | 0.84 | PPARG (0.42) | PPARGRXRAMAPTMEN1KMT2A | |
| SCHEMBL7637830 | 0.84 | CYP1A2 (0.47) | PPARGLCKTUBB4ATUBBTUBA3C | |
| SCHEMBL9404176 | 0.84 | CYP1A2 (0.47) | PPARGLCKTUBB4ATUBBTUBA3C | |
| SCHEMBL7930958 | 0.84 | PPARG (0.35) | PPARGRXRAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020107248-A1 | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | OSI PHARMACEUTICALS, INC. | 2002-08-08 | — | — | US | disclosed |
| US-6232312-B1 | ADMINISTERING A COMBINATION OF INDENE AND PYRIMIDO(5,4-D)PYRIMIDINE DERIVATIVES TO TREAT PREPANCREATIC CANCER | CELL PATHWAYS, INC. | 2001-05-15 | — | — | US | disclosed |
| US-5643959-A | Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | CELL PATHWAYS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0508586-B1 | Substituted indenyl compounds | FGN INC (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5401774-A | Treatment of potentially cancerous growths | UNIVERSITY OF ARIZONA (US) | 1995-03-28 | — | — | US | disclosed |
| EP-0508586-A1 | Substituted indenyl compounds | FGN, INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| EP-0485172-A2 | Esters and amides of substituted indenyl acetic acids | FGN, INC. (US) | 1992-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107248-A1 | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | VHL, IDH3A, GLI2 | PPARG 18/4885LCK 3923/4885RXRA 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.